Blood cancer patients reveal hidden financial toll of treatment

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PATIENT ELIGIBILITY CRITERIA * Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) * Patients' medical records must be available to the registering institution * Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who: * Are presently being treated with infused or orally-administered anticancer therapy, OR * Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR * Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment * Not currently enrolled in a clinical trial in which drug is supplied by the study * Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible * Patients must be able to read and comprehend English or Spanish SITE ELIGIBILITY CRITERIA * Intent to complete the Practice Survey * Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data). * Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish. PHYSICIAN ELIGIBILITY CRTERIA * The physician currently treats patients with chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM). * The physician is a treating physician at a site which has opened this protocol (LCCC 2063) and/or a site which opened the Alliance protocol (A231602CD; ClinicalTrials.gov Identifier: NCT03870633). Eligible physicians do not need to have their own patients enrolled onto this protocol.